Application of HPLC measurement of plasma concentration of gabexate mesilate

Nishijima, Masako K.; Takezawa, Jun; Taenaka, Nobuyuki; Yasuhiro, Shimada; Yoshiya, Ikuto

doi:10.1016/0049-3848(83)90330-4

Cited by 18 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HPLC method for GM described by Nishijima et al 13) was modified as follows: Samples were diluted appropriately with pH 3.5 phosphate buffer and then injected into HPLC (Column, COSMOSIL 5C 18 -MS/5C 18 , Nacalai Tesque; UV detector, SPD-6A, Shimadzu, detected at 245 nm; mobile phase, acetonitrile/0.05 M pH 3.5 phosphate buffer (32 : 68, v/v); flow rate, 0.8 ml/min; injection volume, 20 ml). Methyl p-hydroxybenzoate was used as an internal standard substance.…”

Section: )mentioning

confidence: 99%

Distribution of Protease Inhibitors in Lipid Emulsions: Gabexate Mesilate and Camostat Mesilate

Yin

Noda

Hazemoto

et al. 2005

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

Section: )mentioning

confidence: 99%

Distribution of Protease Inhibitors in Lipid Emulsions: Gabexate Mesilate and Camostat Mesilate

Yin

Noda

Hazemoto

et al. 2005

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

“…When administered by continuous intravenous infusion, gabexate reaches a steady state within 15 minutes, with a half-life of 55 seconds [10], and is eliminated in its inactive form by the kidneys. In a RCT with 418 patients, an infusion of gabexate 30 to 90 minutes before ERCP and for 12 hours thereafter was associated with a significantly lower rate of pancreatitis (2.4%) compared with the control group (7.6%) [11].…”

Section: Results Of Pharmacological Approaches To Pepmentioning

confidence: 99%

Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?

Cheon

2013

Korean J Intern Med

View full text Add to dashboard Cite

Acute pancreatitis remains the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP), with reported incidence rates that have changed little over several decades. Patient- and procedure-related risk factors for post-ERCP pancreatitis (PEP) are well-defined. Effective measures to prevent PEP have been identified, including improvements in cannulation techniques and pancreatic stenting, as well as pharmacological intervention. Pharmacotherapy has been widely studied in the prevention of PEP, but the effect in averting PEP has been inconclusive. Although pharmacological prophylaxis is appealing, attempts to find an ideal drug are incomplete. Most available data on the efficacy of pharmacological agents for PEP prophylaxis have been obtained from patients at average risk for PEP. However, recently, a randomized prospective controlled trial of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent PEP in high-risk patients was published. The results revealed that rectal indomethacin reduced the incidence of PEP significantly. Thus, rectal administration of diclofenac or indomethacin immediately before or after ERCP is used routinely to prevent PEP. However, additional studies with NSAIDs using large numbers of subjects are necessary to confirm the prophylactic effect of these drugs and to establish whether they act synergistically with other prophylactic interventions, including pancreatic stenting.

show abstract

“…It was first characterized as a trypsin inhibitor and is not a selective thrombin inhibitor; nevertheless, the compound is proposed as an anticoagulant and an tithrombotic agent. [42][43][44][45] p-Amidinophenylesters may also inhibit thrombin and prolong clotting times. 46 FUT 175, chemically amidinonaphthyl-guanidinobenzoate, a rather nonselective proteinase inhibitor, is also proposed for anticoagulant and antithrombotic use.…”

Section: Fig 1 Structures Of Prototype Compounds Of the Arginine Dementioning

confidence: 99%

Pharmacologic Aspects of the Development of Selective Synthetic Thrombin Inhibitors as Anticoagulants

Hauptmann

Markwardt²

1992

Semin Thromb Hemost

View full text Add to dashboard Cite

Application of HPLC measurement of plasma concentration of gabexate mesilate

Cited by 18 publications

References 7 publications

Distribution of Protease Inhibitors in Lipid Emulsions: Gabexate Mesilate and Camostat Mesilate

Distribution of Protease Inhibitors in Lipid Emulsions: Gabexate Mesilate and Camostat Mesilate

Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?

Pharmacologic Aspects of the Development of Selective Synthetic Thrombin Inhibitors as Anticoagulants

Contact Info

Product

Resources

About